References
- MokTSWuYLThongprasertSGefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J Med200936194795719692680
- Paz-AresLSoulièresDMelezínekIClinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysisJ Cell Mol Med201014516920015198
- DrilonAWangLArcilaMEBroad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in “driver-negative” lung adenocarcinomasClin Cancer Res201521163631363925567908
- PaweletzCPSacherAGRaymondCKBias-corrected targeted next-generation sequencing for rapid, multiplexed detection of actionable alterations in cell-free DNA from advanced lung cancer patientsClin Cancer Res201622491592226459174
- EngelmanJAJännePAMechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancerClin Cancer Res2008142895289918483355
- JanmaatMLRodriguezJAGallegos-RuizMKruytFAEGiacconeGEnhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cellsInt J Cancer200611820921416003751
- JiMGuanHGaoCShiBHouPHighly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC)BMC Cancer20111114721507233
- EngelmanJATargeting PI3K signalling in cancer: opportunities, challenges and limitationsNat Rev Cancer2009955056219629070
- MokTSWuYLAhnMJAURA3 investigatorsOsimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancerN Engl J Med201637662964027959700
- JinYShaoYShiXMutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencingOncotarget2016738617556176327528220
- YuHAArcilaMERekhtmanNAnalysis of tumor specimens at the time of acquired resistance to EGFR TKI therapy in 155 patients with EGFR mutant lung cancersClin Cancer Res20131982240224723470965
- YangJJZhangXCSuJLung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylationClin Cancer Res2014201383139224443522
- NormannoNBrownHHaddadV580_PR: Clinical and demographic features that influence EGFR mutation detection in plasma from patients (pts) with aNSCLC: The ASSESS experienceJ Thoracic Oncol201611S151